Cargando…
Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach
Since the emergence of SARS-CoV2, to date, no effective antiviral drug has been approved to treat the disease, and no vaccine against SARS-CoV2 is available. Under this scenario, the combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, has attracted attention since they have been p...
Autor principal: | Bello, Martiniano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511853/ https://www.ncbi.nlm.nih.gov/pubmed/33022569 http://dx.doi.org/10.1016/j.jmgm.2020.107762 |
Ejemplares similares
-
Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA
por: Bello, Martiniano, et al.
Publicado: (2020) -
Targeting SARS-CoV-2 main protease by teicoplanin: A mechanistic insight by docking, MM/GBSA and molecular dynamics simulation
por: Azam, Faizul, et al.
Publicado: (2021) -
Enzymatic activity of the SARS coronavirus main proteinase dimer
por: Graziano, Vito, et al.
Publicado: (2006) -
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
por: Genheden, Samuel, et al.
Publicado: (2015) -
Exploring potential SARS-CoV-2 Mpro non-covalent inhibitors through docking, pharmacophore profile matching, molecular dynamic simulation, and MM-GBSA
por: Shi, Yunfan, et al.
Publicado: (2023)